A systematic review and meta-analysis considering the SSRI, SNRI and TCA classes of antidepressants and the risk for congenital heart defects

Courtney De Vries, Svetla Gadzhanova, Matthew J. Sykes, Michael Ward, Elizabeth Roughead

Abstract

Background Antidepressant use during the first trimester is reported in 4% to 8% of pregnancies. The use of some selective serotonin reuptake inhibitors (SSRI) during this stage of gestation has been identified as increasing the odds for congenital heart defects, however little is known about the safety of non-SSRI antidepressants.

Objective To assess the odds of congenital heart defects associated with the use of any antidepressant during the first trimester of pregnancy. To investigate individual classes of antidepressants: SSRIs, serotonin norepinephrine reuptake inhibitors (SNRI), tricyclic antidepressants (TCA) and individual antidepressants.

Data sources PubMed and Embase were searched without restrictions from inception till 2 January 2020.

Study selection Prospective and retrospective cohort and case-control studies were included if they documented the maternal usage of antidepressants during the first trimester of pregnancy and assessed the presence of congenital heart defects.

Data extraction and meta-analysis Data were extracted by two independent reviewers and the endpoint assessed was congenital heart defects. Where studies reported multiple results for different types of heart defects or individual antidepressants, results were combined when possible. Analyses assessing individual antidepressants and classes of antidepressants (SSRIs, SNRIs and TCAs) were undertaken.

Results A total of 16 studies were identified, encompassing 4,564,798 pregnancy outcomes. The odds ratio for maternal use of any antidepressant and the presence of congenital heart defects from the mixed-methods meta-analysis was 1.22 (95% confidence interval (CI): 1.11 to 1.33).

Analyses of antidepressants by class produced an odds ratio of 1.50 (95% CI: 1.19 to 1.89) for maternal SNRI use during the first trimester of pregnancy and the formation of congenital heart defects. A significant odds ratio of 1.22 (95% CI: 1.12 to 1.33) was reported for SSRIs. For the TCA class, no increased odds ratio was found.

Analyses of individual antidepressants produced significant odds ratios of 1.53 (95% CI: 1.25 to 1.88), 1.28 (95% CI: 1.01 to 1.62), 1.28 (95% CI: 1.14 to 1.45) and 1.23 (95% CI: 1.01 to 1.50) for paroxetine, fluoxetine, sertraline and bupropion respectively.

Conclusion While some insight has been gained into which classes of antidepressant and individual antidepressants pose more risk than others for causing congenital heart defects, information regarding some antidepressants is still lacking.

Introduction

Antidepressants are used during pregnancy, with the prevalence of maternal antidepressant use increasing over time.¹⁻³ In Denmark, the use of selective serotonin reuptake inhibitors (SSRI) in pregnancy increased from approximately 0.5% to 3% between 2000 and 2010.¹ In the United States of America (USA), the Birth Defects Study identified that the use of any antidepressant during the first trimester of pregnancy increased from less than 0.5% before 1987, to 3% in 1999 and 8% in 2008.² This study identified that use of selective serotonin reuptake inhibitors (SSRI) was 2% in 1999 and 6% in 2008.² Dispensing records between 2006 and 2011 in the USA, identified the use of any antidepressant and SSRIs during the first trimester of pregnancy as 5% and 4% respectively.³

Paroxetine was the first SSRI to reach the American market in 1992. In 2005, an alert was released stating that the use of paroxetine during pregnancy had been associated with an increased risk of major congenital malformations, especially those relating to the heart.⁴ A 2016 meta-analysis reported an odds ratio of 1.23 (95% confidence interval (CI): 1.06 to 1.43) for paroxetine use during the first trimester of pregnancy and any cardiac malformations.⁵ Specific cardiac defects were also investigated in this meta-analysis and some were reported to be significant, including: atrial septal defects, right ventricular outflow tract obstructions, bulbus cordis anomalies and anomalies of cardiac septal closure.⁵

Medications from the same class may exert similar toxicities, meaning that other antidepressants may also increase the risk for congenital heart defects. It is desirable to minimise medicine use in pregnancy but discontinuing antidepressant therapy in unwell women may be complicated by the risks of suicidal ideation, relapse of depression and anxiety or panic attacks.^{6,7} The severity of these risks mean that it may not be possible to cease antidepressant therapy. Evidence regarding the safety of antidepressant use in human pregnancies is required for all women.

Pharmacoepidemiological studies provide data for birth outcomes following antidepressant use during the first trimester of pregnancy, which is the relevant period to investigate for cardiac defects as the heart is formed during weeks 4 to 8 of gestation. Previous meta-analyses have revealed significant relationships between usage of paroxetine,^{5,8,9} fluoxetine,^{10,11} sertraline¹² and any antidepressant¹³ during the first trimester of pregnancy and an increased formation of heart defects. Only one of these meta-analyses considered non-SSRI antidepressants,¹³ and several cohort and case-control studies have been published since the last published meta-analysis.¹⁴⁻¹⁸ The largest meta-analysis to date was carried out by Shen et al.¹² and investigated the first trimester use of sertraline and congenital heart defects. This meta-analysis included 12 cohort studies with a total of 6,468,241 pregnant women and found a statistically significant increased risk of cardiovascular defects, with an odds ratio of 1.36 (95% CI: 1.06 to 1.74).

The aim of this systematic literature review and meta-analysis was to investigate the relationship between usage of any antidepressant during the first trimester of pregnancy and the development of congenital heart defects. An investigation into specific classes of antidepressants was also completed to assess whether a class-effect exists between first trimester antidepressant use and congenital heart defects. The relationship between usage of specific antidepressants during the first trimester of pregnancy and heart defects was also investigated.

Methods

Literature review

A literature review was completed using PubMed and Embase. The databases were searched from inception to 2 January 2020 using MeSH terms listed in supplement 1. Search terms were searched independently and then combined within each database to retrieve articles reporting the use of antidepressive medications in pregnancy and adverse outcomes. The search strategy and results are detailed in supplement 1. The results were limited to human data and no further limits were imposed on the search. Duplicates were removed before moving onto the title and abstract reviews. PRISMA guidelines were followed for all procedures and reporting (supplement 2).

Study selection criteria and data extraction

The title and abstract inclusion criteria were cohort or case-control studies with a comparison group of women who had not used antidepressants during pregnancy, study participants aged 15 years or older, maternal use of antidepressants during the first trimester of pregnancy, and outcomes which included

congenital heart defects or other malformations. Live births, stillbirths and terminations of pregnancy were all classified as suitable endpoints of pregnancies. If the usage of antidepressant agents was not confirmed, repeated prescriptions or dispensations of an agent were assumed to correlate directly to maternal usage.

The title and abstract exclusion criteria were: reviews, study protocols, case series, case reports, editorials, commentaries, letters to the editor, conference papers, study participants under 15 years of age, studies which contained only abortive, mortal and neurobehavioral outcomes and if the data collected did not pertain to antidepressant medications. The form for title and abstract reviews is provided in supplement 3.

The quality of eligible studies was assessed using a modified version of the Newcastle-Ottawa quality assessment scale. While the Newcastle Ottawa Scale assesses important study features it is not intuitive to use and reviews have documented that there is a low inter-reviewer reliability and poor agreement about study quality between authors and reviewers when using this scale.^{19 20} For this reason the scale was altered to make it tailored for assessing congenital heart defects as the outcome of interest and to improve categorisation of study design. To improve the ease of which reviewers could assess study design the scale was converted to a tabular format which allowed for an analysis on the study quality to be compiled into a single document. The advantage of this method is that it allowed customisation of the documentation of the study methods before grouping the criteria into high, medium or low categories and the assessment outcomes into ideal, good, acceptable or poor outcomes (supplement 4). High impact criteria assessed the selection of study participants and the determination of outcomes and antidepressant use. Follow-up was classified as being a medium impact criterion. Low impact criteria assessed other study features including maternal smoking, alcohol or medication use and whether the non-medicated comparison group was depressed or not.

If three of the high impact criteria were ideal, the end of follow-up was not poor and at least one of the low impact criteria were ideal for cohort studies, the study was included. Cohort studies were excluded if any of the high or medium impact criteria were poor. If four of the high impact criteria were ideal and at least two of the low impact criteria were ideal for case-control studies, the study was included. Case-control studies were excluded if any of the high impact criteria were poor. The differences in cohort and case-control study designs produced slightly different study criteria and therefore inclusion decisions. The method for ascertaining antidepressant use, a high impact criterion, was completed for both cohort and case-control studies. For case-control studies an additional criterion was added to confirm that the same method of ascertainment was used for cases and controls. End of follow-up, a medium impact criterion, was only completed for cohort studies to assess pregnancy and birth outcomes. Non-response rate, a low impact criterion, was only completed for case-control studies to identify any differences between the non-response rates of cases and controls (supplement 4).

CDV and SG independently undertook data extraction and quality ranking. Any conflicts were discussed and reviewed by ER.

Once potentially suitable studies were identified, the data sources, study years and settings were compared to ensure that multiple studies did not use the same data. If data sources such as birth registries overlapped between studies, then the most recent study providing the largest sample size was retained.

All reported crude odds ratios and adjusted odds ratios were extracted from the studies. Additionally, the data needed to calculate odds ratios for antidepressant usage during the first trimester of pregnancy and the formation of congenital heart defects were retrieved from the studies.

Most studies included a single comparison group which had not used antidepressants during pregnancy, however some studies reported multiple comparison groups. Ban, et al. 2014¹⁴ provided data on two unmedicated groups, either depressed or non-depressed. The comparison group in the meta-analysis comprises the sum of unmedicated depressed and non-depressed women. Furu, et al 2015¹⁶ provided data on a full study cohort and a sub-cohort comprised of sibling pairs. Data from the full cohort were included. Davis et al. 2007²¹ reported data on SSRIs and tricyclic antidepressants (TCA), however these could not be combined for the primary analysis because the total number of women in the unmedicated comparison group was inconsistent. Therefore, these data are reported individually in all analyses.

Some studies assessed individual heart defects or individual antidepressants. Whenever possible, results from the individual antidepressants and heart defects were aggregated to estimate overall harm for the “any antidepressant” analysis. Classes of antidepressant and individual antidepressants were analysed if data for the meta-analyses were available from at least three studies for each class or antidepressant.

Confounding factors reported in the studies including the use of other medications, maternal smoking and maternal diabetes were recorded.

Statistical analyses

RevMan 5.3²² was utilised to perform the meta-analyses. The primary analysis investigated the relationship between maternal use of any antidepressant during the first trimester of pregnancy and the presence of congenital heart defects. The antidepressant classes were stratified into SSRI, serotonin-norepinephrine reuptake inhibitor (SNRI) and TCA groups. Antidepressants were investigated individually, and the results were also stratified by cohort and case-control studies.

Mixed-effects models were used for all meta-analyses because they are more suited to dealing with heterogenous data. An overall odds ratio with a 95% CI measuring the relationship between first trimester antidepressant usage and the presence of heart defects was calculated in all analyses and the significance of these relationships were investigated by the p value for overall effect. Heterogeneity was measured by the I^2 values and their corresponding p values and analyses were defined as being heterogenous if their p values were significant (<0.05).

Outlying studies were defined as having a markedly different intervention effect estimate or an abnormally large confidence interval. To complete a sensitivity analysis, the primary meta-analysis was investigated for outliers and a funnel plot was examined to identify outlying studies (supplement 5). The funnel plot is also a small-study effect test. The Mantel-Haenszel mixed-effects meta-analysis was applied, both with and without the outlying studies, to determine the effect of outliers on the overall significance of the results and the heterogeneity.

Results

Figure 1 shows the article selection process. Following the title and abstract screening, 76 articles were eligible for a full text review. 16 studies, comprising 4,564,798 pregnancy outcomes met the final inclusion criteria and were included.

An overview of the characteristics of the included studies and detailed information on relevant medication use is reported in table 1. Twelve studies were cohort studies^{5 14 16 21 23-29} and four studies were case controls.^{18 30-32} Eight of the studies were prospective^{14-16 18 24 27 28 33} and eight were retrospective.^{21 23 25 26 29-32} For two studies the comparison group included depressed women who were unmedicated.^{14 15}

The unadjusted and adjusted odds ratios from individual studies are provided in table 2, with significant odds ratios shown in bold text.

Table 1 Overview of studies included in the systematic review and meta-analyses

Author, Year Published	Study Type	Study Years (Setting)	End Of Follow Up	Definition Of Maternal Antidepressant Use	Definition Of Non-Antidepressant Use	Proportion Of Cohort With Concomitant Medications
Jordan, et al. 2016 ²⁴	Prospective cohort	2004 – 2010 (Norway), 2000 – 2010 (Wales and Denmark)	Live births, still births, fetal deaths after 20 weeks (24 weeks in Wales)	One or more prescription for an antidepressant (Wales) or dispensed (Norway and Denmark), 91 days either side of the first day of the LMP	Did not use any antidepressant during the 91 days either side of the first day of the LMP	n.d.
Furu, et al. 2015 ¹⁶	Prospective cohort	1996 – 2010 (Denmark, Finland, Iceland, Norway and Sweden)	Live births only	Use of a single, consistent SSRI between at least one month before conception and day 84 of the pregnancy, identified by redeemed prescriptions	No redeemed prescriptions for antidepressants from 30 days before the first day of the LMP to 97 days after the LMP	15% of SSRI-using and 1% of non-SSRI-using mothers
Berard, et al. 2015 ¹⁵	Prospective cohort	1998 – 2010 (Canada)	Live births only	Continuous prescription of antidepressants for at least 12 months before the LMP and during pregnancy	Depressed and not using antidepressant medications	93% of mothers using sertraline 93% of mothers using non-sertraline SSRIs 94% of mothers using non-SSRI antidepressants 84% of mothers in the comparison group
Huybrechts, et al. 2014 ²³	Retrospective cohort	2000 – 2007 (United States)	Live births only	Overlap between pharmacy dispensing of antidepressants and the first trimester of pregnancy	No dispensing of antidepressants during the first trimester of pregnancy	Among SSRI users: 4% used antidiabetics, 16% used anticonvulsants, 21% used antipsychotics, 7% used anxiolytics, 32% used benzodiazepines, 29% used other hypnotic agents, 8% used barbiturates and 8% used a suspected teratogen
Ban, et al. 2014 ¹⁴	Prospective cohort	1990 – 2009 (United Kingdom)	Live births only	Presence of SSRI or TCA prescriptions in records from four weeks before to 12 weeks after the first day of the estimated LMP. Dual usage of SSRIs excluded	Depressed or non-depressed and not using antidepressants	n.d.
Vasilakis-Scaramozza, et al. 2017 ²⁹	Retrospective cohort	1991 – 2002 (United Kingdom)	Live births, stillbirths, and therapeutic abortions > 20 weeks' gestation	Prescription receipt for an antidepressant from 180 to 335 days prior to the delivery date for live births and from 70 to 225 days prior to the delivery date for stillbirths and therapeutic abortions	No receipt for an antidepressant during pregnancy	Less than 1% of women using an antidepressant used insulin or a teratogen during the first trimester of pregnancy
Margulis, et al. 2013 ²⁶	Retrospective cohort	1996 – 2010 (United Kingdom)	Live births only	Women with one or more prescriptions for a single SSRI, overlapping with the first trimester	Women with no antidepressant prescriptions in the three	Among SSRI users: 18% had any prescription for non-SSRI psychotropics, 1% had any

				of pregnancy	months before through to the first or second trimester of pregnancy	prescriptions for anticonvulsants in and 4% had non-antidepressant drugs prescribed in the baseline year
Nordeng, et al. 2012 ²⁷	Prospective cohort	1999 – 2005 (Norway)	Live births, fetal deaths, or induced abortions after gestational week 12	Dispensed prescription for any antidepressant from 30 days before the first day of the LMP until 97 days after the LMP	No reported use of any antidepressants in the six months before or during pregnancy	n.d.
Diav-Citrin, et al. 2008 ³³	Prospective cohort	1994 – 2002 (Israel and Italy), 2002 – 2005 (Germany)	Live births only	Dispensed prescription for paroxetine or fluoxetine from 30 days before the first day of the LMP till 97 days after the LMP	Women who contacted a centre regarding the use of medications known not to be harmful in similar timeframes	n.d.
Oberlander, et al. 2008 ²⁸	Prospective cohort	1998 – 2001 (Canada)	Live births only	Dispensed antidepressant prescription from the LMP to 90 days after the LMP	No dispensed prescriptions for antidepressants or benzodiazepines	Women taking anticonvulsants were excluded
Davis, et al. 2007 ²¹	Retrospective cohort	1996 – 2000 (United States)	Live births only	Dispensed antidepressant during the first trimester of pregnancy	Women who were not prescribed antidepressants at any time during pregnancy	n.d.
Kulin, et al. 1998 ²⁵	Retrospective cohort	Unknown time period (United States and Canada)	Live births, spontaneous abortions, therapeutic abortions and stillbirths	Use of sertraline or fluoxetine during the first trimester of pregnancy	Use of non-harmful medications during pregnancy	n.d.
Louik, et al. 2014 ¹⁸	Prospective case-control	1993 – 2004 (United States)	Live births only	Use of any antidepressant from 28 days before the LMP to 112 days after the LMP	No use of any antidepressant at any time from 56 days prior to the LMP	n.d.
De Jonge, et al. 2013 ³¹	Retrospective case-control	1998 – 2008 (Netherlands)	Live births, stillbirths, spontaneous abortions and terminations of pregnancy	The antidepressant was registered to be used during the first 13 weeks after the first day of the LMP	The antidepressant was not registered to be used during the first 13 weeks after the first day of the LMP	n.d.
Polen, et al. 2013 ³²	Retrospective case-control	1997 – 2007 (United States)	Live births, still births ≥ 20 weeks gestation and elective terminations	Reported use of venlafaxine from one month before conception through to the third month of pregnancy	No reported use of any antidepressant from three months before conception through the end of pregnancy	n.d.
Alwan, et al. 2010 ³⁰	Retrospective case-control	1997 – 2004 (United States)	Live births and fetal deaths after 20 weeks gestation	Reported use of bupropion anytime between one month before and three months after conception	Did not use any antidepressant at any time during pregnancy	n.d.

LMP, Last menstrual period; n.d., no data; SSRI, Selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant

Table 2 Systematic review of the individual studies, reporting antidepressant use during the first trimester of pregnancy and odds ratios for congenital heart defects

Author, Year Published	Cohort / Case		Comparison		Antidepressant Used	Crude Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI)	Odds Ratio Adjusted For	Meta Analysis That The Data Was Used In
	N Events	N Total	N Events	N Total					
Jordan, et al. 2016 ²⁴	121	12,962	4,503	506,155	SSRI or SNRI	1.03 (0.86 to 1.24)	1.00 (0.82 to 1.21)	Smoking and socioeconomic status	Any antidepressant
	101	10,959	4,047	449,643	SSRI monotherapy	1.00 (0.82 to 1.22)	n.d.	n.d.	SSRI group
	18	1,448	4,503	506,155	SNRI	1.40 (0.88 to 2.23)*			SNRI group
Furu, et al. 2015 ¹⁶	530	34,535	26,745	2,266,875	SSRI or venlafaxine	1.32 (1.21 to 1.44)*	n.d.	n.d.	Any antidepressant
	490	31,772			SSRI	1.33 (1.21 to 1.45)*			SSRI group
	40	2,763			Venlafaxine (monotherapy or polytherapy)	1.23 (0.90 to 1.68)	1.14 (0.82 to 1.57)	Maternal age, year of birth, birth order, smoking, maternal diabetes, country and use of other medications	SNRI group
Berard, et al. 2015 ¹⁵	89	3,625	344	14,868	Any antidepressant	1.06 (0.84 to 1.35)*	n.d.	n.d.	Any antidepressant
	61	2,329			SSRI	1.14 (0.86 to 1.50)*			SSRI group
Huybrechts, et al. 2014 ²³	580	64,389	6,403	885,115	Any antidepressant	1.25 (1.15 to 1.36)	n.d.	n.d.	Any antidepressant
	416	46,144			SSRI	1.25 (1.13 to 1.38)			SSRI group
	75	6,904			SNRI	1.51 (1.20 to 1.89)			SNRI group
	42	5,954			TCA	0.97 (0.72 to 1.32)			TCA group
Ban, et al. 2014 ¹⁴	90	10,401	2,556	338,726	SSRI or TCA mono- or polytherapy	1.15 (0.93 to 1.42)*	n.d.	n.d.	Any antidepressant
	68	7,683			SSRI monotherapy	1.17 (0.92 to 1.50)*			SSRI group
	20	2,428			TCA monotherapy	1.09 (0.70 to 1.70)*			TCA group
Vasilakis-Scaramozza, et al. 2013 ²⁹	18	3,287	28	6,617	SSRI or TCA	1.30 (0.72 to 2.35)*	n.d.	n.d.	Any antidepressant
	7	1,825			SSRI	0.91 (0.40 to 2.08)*			SSRI group
	11	1,608			TCA	1.62 (0.81 to 3.26)*			TCA group
Margulis, et al. 2013 ²⁶	16	3,046	48	8,991	SSRI	0.98 (0.56 to 1.73)*	1.09 (0.66 to 1.79)	Logistic regression	Any antidepressant

									and SSRI group
Nordeng, et al. 2012 ²⁷	6	556	541	61,648	Any antidepressant	1.23 (0.55 to 2.77)*	1.24 (0.55 to 2.82)	Maternal depression, maternal age at delivery, parity and use of psychotropic medications during pregnancy	Any antidepressant
	6	462			SSRI	1.49 (0.66 to 3.34)*	1.51 (0.67 to 3.43)		SSRI group
Diav-Citrin, et al. 2008 ³³	14	601	8	1,359	Paroxetine or fluoxetine	4.03 (1.68 to 9.65)*	n.d.	n.d.	Any antidepressant and SSRI group
Oberlander, et al. 2008 ²⁸	19	2,709	512	107,320	SSRI or SNRI monotherapy	1.47 (0.93 to 2.33)*	n.d.	n.d.	Any antidepressant
	18	2,459			SSRI monotherapy	1.54 (0.96 to 2.47)*			SSRI group
	1	250			Venlafaxine monotherapy	0.84 (0.12 to 5.98)*			SNRI group
Davis, et al. 2007 ²¹	17	805	1,171	49,031	SSRI	0.88 (0.54 to 1.43)*	n.d.	n.d.	Any antidepressant and SSRI group
	2	167	1,186	49,669	TCA	0.50 (0.12 to 2.00)*			Any antidepressant and TCA group
Kulin, et al. 1998 ²⁵	2	267	4	267	SSRI	0.50 (0.09 to 2.73)*	n.d.	n.d.	Any antidepressant and SSRI group
Louik, et al. 2014 ¹⁸	447	8,805	370	8,611	Any antidepressant	1.19 (1.03 to 1.37)*	n.d.	n.d.	Any antidepressant
	349		290		SSRI	1.18 (1.01 to 1.39)*			SSRI group
	29		32		TCA	0.89 (0.54 to 1.47)*			TCA group
De Jonge, et al. 2013 ³¹	14	873	281	29,223	SSRI	1.68 (0.98 to 2.88)*	n.d.	n.d.	Any antidepressant and SSRI group
Polen, et al. 2013 ³²	74	15,758	14	8,002	Venlafaxine	2.69 (1.52 to 4.77)*	n.d.	n.d.	Any antidepressant and SNRI group
Alwan, et al. 2010 ³⁰	34	6,853	26	5,869	Bupropion	1.12 (0.67 to 1.87)*	1.4 (0.8 to 2.5)	Maternal race, obesity, smoking and family income	Any antidepressant

CI, confidence interval; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin norepinephrine reuptake inhibitor; n.d., no data; TCA, tricyclic antidepressant

*Odds ratio and 95% CI calculated using RevMan 5.3

The total pooled odds ratio from the unadjusted meta-analysis for any antidepressant use was 1.22 (95% CI: 1.11 to 1.33, $p < 0.0001$) (figure 2). The corresponding number needed to harm is 442 women taking antidepressants during the first trimester of pregnancy.

Statistically significant odds ratios of 1.22 (95% CI: 1.12 to 1.33, $p < 0.00001$) and 1.50 (95% CI: 1.19 to 1.89, $p < 0.0006$) are reported in figure 3 for the SSRI and SNRI subgroups respectively. The corresponding numbers needed to harm are 198 and 447 women taking SSRIs or SNRIs during the first trimester of pregnancy. The TCA subgroup had a non-statistically significant odds ratio of 1.01 (95% CI: 0.82 to 1.25, $p = 0.52$) (figure 3). Exclusion of the outliers did not change the significance of the results for the overall or class analyses (supplement 5).

Analyses of individual antidepressants produced statistically significant odds ratios of 1.53 (95% CI: 1.25 to 1.88, $p < 0.001$) for paroxetine, 1.28 (95% CI: 1.01 to 1.62, $p = 0.04$) for fluoxetine, 1.28 (95% CI: 1.14 to 1.45, $p < 0.0001$) for sertraline and 1.23 (95% CI: 1.01 to 1.50, $p = 0.04$) for bupropion (figure 4). The pooled odds ratios for citalopram, escitalopram and venlafaxine were not significant (figure 4). Removal of the outlying data²⁸ in the citalopram analysis resulted in a statistically significant odds ratio of 1.28 (95% CI: 1.12 to 1.46, $p = 0.0002$), reported in supplement 5.

Analyses of cohort versus case-control studies resulted in odds ratios of 1.19 (95% CI: 1.08 to 1.31, $p = 0.003$) and 1.48 (95% CI: 1.04 to 2.11, $p = 0.03$), respectively (figure 5). Analyses of prospective versus retrospective studies resulted in odds ratios of 1.21 (1.09 to 1.34, $p = 0.0005$) and 1.24 (95% CI: 0.96 to 1.59, $p = 0.10$), respectively (figure 6).

Discussion

This meta-analysis of 16 studies from 13 countries including 4,564,798 pregnancy outcomes spanning twenty years confirms that using antidepressants during the first trimester of pregnancy is associated with an increased risk of congenital heart defects. Specifically, the odds of women who use any antidepressant in their first trimester of pregnancy having children with congenital heart defects is 1.1 to 1.3 times greater than the unmedicated group, at a 95% confidence level.

Our results for the usage of any antidepressant¹³, paroxetine,^{5 8 9} fluoxetine^{10 11}, and sertraline¹² are comparable to previous meta-analyses, an overview of which is provided in table 3. These results indicate that both SNRIs and SSRIs increase the odds of congenital heart defects following maternal usage of these antidepressants during the first trimester of pregnancy, the critical period for cardiac development. Additionally, no increased odds for congenital heart defects following the usage of TCAs during the first trimester of pregnancy were found. This is the first meta-analysis to investigate and compare non-SSRI classes of antidepressants. These data are useful for providing insight into class-effects and possible mechanistic similarities for the formation of heart defects, as both SNRIs and SSRIs inhibit serotonin reuptake.^{34 35} However, limitations still exist in that there is still a lack of data about commonly used antidepressants, as demonstrated from Australian data; statistics for dispensed medications in 2013 identified that 16% of women of child bearing age who were dispensed psycho-analeptics were dispensed the SNRI desvenlafaxine.³⁶ While our study investigated maternal SNRI usage during pregnancy and congenital heart defects, there was limited data on specific SNRIs and none of the studies investigating SNRIs had specific data on desvenlafaxine.^{16 23 24 28 32}

Venlafaxine and bupropion were the only SNRIs for which there was enough data to include in the individual antidepressant meta-analysis (figure 4), with respective pooled odds ratios of 1.29 (95% CI: 0.98 to 1.69) and 1.23 (95% CI: 1.01 to 1.50). Bupropion is not registered as an antidepressant in

Australia and is instead used for nicotine dependence and the dose size for this is 150 mg. Comparatively, the reported mean dose of bupropion in the USA from the Louik et al.¹⁸ study ranged from 254mg in monotherapy to 354mg in polytherapy.

SSRIs have been the most investigated class of antidepressants in relation to congenital heart defects, probably as a result of the 2005 paroxetine warning.⁴ Significant odds ratios for paroxetine, fluoxetine and sertraline were found (figure 4). Previous meta-analyses have documented a statistically significant relationship between maternal use of paroxetine,^{5 8 9} fluoxetine,^{10 11} and sertraline¹² during the first trimester of pregnancy and congenital heart defects.

The pooled odds ratios for citalopram and escitalopram were not significant (figure 4) and a 2013 meta-analysis also calculated a non-significant pooled odds ratio for maternal citalopram usage and congenital heart defects.⁸ The removal of outlying data in the citalopram analysis resulted in a statistically significant odds ratio of 1.22 (1.03 to 1.45), therefore it is possible that citalopram may increase the likelihood for congenital heart defects (supplement 5); further escitalopram had a limited sample size.

The largest previous meta-analysis was carried out by Shen et al.¹² and investigated the first trimester use of sertraline and congenital heart defects. Their meta-analysis included 12 cohort studies and had a total of 6,468,241 pregnant women, which is larger than the 4,564,798 pregnancy outcomes in this meta-analysis. We used six of the same studies^{14-16 23 27 28} however the remaining six from the Shen et al. meta-analysis were excluded for the following reasons: the Colvin et al. 2011³⁷ study had a comparison group which had potentially used non-SSRI antidepressants; the Merlob et al. 2009³⁸ study did not meet our inclusion criteria primarily because of self-reported SSRI usage and an unblinded assessment of pregnancy outcomes; the remaining four studies³⁹⁻⁴² all reported data from the Swedish birth registry and these data therefore overlap with the Furu 2015 study (supplement 4).¹⁶ Like the Shen et al.¹² meta-analysis, our results for sertraline use during the first trimester of pregnancy and congenital heart defects are significant, while demonstrating lower heterogeneity, reflected by the I^2 value (figure 4, table 3).

The Davis et al. 2007²¹ tricyclic antidepressant data and the Kulin et al. 1998²⁵ study were classified as outliers due to their wide variances. The Diav-Citrin et al. 2008³³ and Polen et al. 2013³² studies were classified as outliers because they demonstrated markedly higher intervention effect estimates than the overall odds ratio. Removal of these studies did not change the significance of the results but did decrease the heterogeneity (supplement 5).

Results were stratified by study type because it has been established that cohort studies are more rigorous than case-control studies as the study design results in less potential for sampling, observation and recall bias.^{43 44} Both cohort and case-control studies may be affected by confounding factors, including maternal usage of other medications and maternal smoking. The pooled average odds ratios were similar between both study groups (figure 5). Similarly, prospective studies are more rigorous than retrospective studies because these are conducted before pregnancy outcomes are known, resulting in more control over study features and less potential for recall bias.^{43 44} The pooled average odds ratios were significant for the prospective studies and not significant for the retrospective studies (figure 6).

A strength of our study was the inclusion criteria requiring all studies to be of high quality. Therefore, the meta-analyses reported a direct comparison between women who did or did not use antidepressants during the first trimester of pregnancy. One difficulty in generating high quality pharmacoepidemiological data is proper documentation of data in medical records and administrative

databases, because there may be missing data, misclassification of medication usage or birth outcomes. One limitation of this meta-analysis is confirming whether the women used the antidepressants. Some studies confirmed this by structured interviews,^{18 25 27 30 33} while others only relied on antidepressant dispensings which do not verify consumption.^{16 21 23 24 28 29}

A strength of this meta-analysis was that it was not limited to studies which only investigate live births. Live birth studies are susceptible to selection bias because congenital heart defects can be detected by scans which generally occur between weeks 18 to 22 of pregnancy.⁴⁵ Pregnancies may be terminated if these defects are detected and these cases or events will be missed if only live births are assessed. Additionally, congenital heart defects may be present in stillbirths. Therefore, restricting analyses to live births may underestimate the relationship between maternal antidepressant use and congenital heart defects. Despite the potential for selection bias, two of the previous meta-analyses restricted pregnancy endpoints to live births only.^{9 12} Similar to the results reported here, these meta-analyses found significant results for paroxetine⁹ and sertraline¹² usage and heart defects, however their odds ratios were slightly larger and have wider confidence intervals (figure 4, table 3).

Our study, limited to high-quality studies, updates the literature on all antidepressants, including antidepressants belonging to the SNRI and TCA classes. There is evidence that maternal use of SNRIs during the first trimester of pregnancy increases the likelihood for congenital heart defects. Additionally, this meta-analysis confirms evidence for the SSRI class having an increased likelihood for causing cardiac defects. Some individual SSRIs, paroxetine, fluoxetine and sertraline, demonstrated statistically significant odds ratios. A statistically significant odds ratio was also demonstrated for the SNRI bupropion. No statistically significant odds ratio was produced for maternal usage of TCAs in the first trimester of pregnancy and congenital heart defects. While this meta-analysis has investigated classes of antidepressants and individual antidepressants in the context of congenital heart defects, further information is needed for some individual antidepressants which are used by women of child-bearing age, such as desvenlafaxine.

Table 3 Previous meta-analyses assessing the relationship between antidepressant usage during the first trimester of pregnancy and cardiovascular defects

Author, Year Published	Data Sources (Search Period)	Study Types (Setting)	Tool For Assessing Study Quality	N Pregnant Women	Antidepressants Investigated	Reported OR/RR (95% CI)	I ² (p Value)	Study Strengths	Study Weaknesses
Shen, et al. 2017 ¹²	PubMed and Web of Science (inception to 31 December 2015)	12 cohort studies (Europe, Australia, North and South America, Israel)	Newcastle Ottawa Scale	6,468,241	Sertraline	1.36 (1.06 to 1.74)	64.4% (0.001)	Limited to cohort studies Modest power size and population heterogeneity explored One antidepressant only	Only live births considered Case-control studies not included Moderate heterogeneity Overlapping study data Comparison group could have used other antidepressants
Gao, et al. 2017 ¹⁰	PubMed and Web of Science (inception to 21 March 2016)	12 cohort studies (Europe, North America, Australia, Israel)	Newcastle Ottawa Scale	6,450,771	Fluoxetine	1.36 (1.17 to 1.59)	23.4% (0.214)	Limited to cohort studies and population heterogeneity explored Multiple defects investigated One antidepressant only Live births, fetal deaths and terminations of pregnancy included. Low heterogeneity observed in results	Case-control studies not included
Berard, et al. 2016 ⁵	Embase and Medline (1996 to November 2015)	10 studies, cohort and case-control (North America, Europe, Australia)	Inclusion criteria: paroxetine use during T1, a comparator group, information to calculate an OR or a given RR or OR, investigated	24,303 women exposed to paroxetine	Paroxetine	1.23 (1.06 to 1.43)	1.0% (0.436)	Limited to case-control and cohort studies One antidepressant only Low heterogeneity observed in results Live births, fetal deaths and terminations of pregnancy included.	Comparison group could have used other antidepressants

			congenital malformations						
Riggin, et al. 2013 ¹¹	PubMed, Medline and Embase (inception to 31 August 2012)	15 cohort studies and 2 case-control studies	Inclusion criteria: any fluoxetine use during T1, compared to a control group not using SSRIs	Cohort: 3,437,257 Case-control: 23,452	Fluoxetine	Cohort: 1.60 (1.31 – 1.95) Case-control: 0.63 (0.39 – 1.03)	n.d. (0.431) n.d. (0.14)	Limited to case-control and cohort studies One antidepressant only Three databases investigated Include data outside of live births	Unclear on study procedures Some control groups may have been exposed to non-SSRI antidepressants
Myles, et al. 2013 ⁸	CINAHL, Embase, Medline, PsycINFO and ISI Web of Science (1985 to June 2011)	15 cohort studies	Based on Meta-Analysis Of Observational Studies in Epidemiology	2,426,925	Fluoxetine Paroxetine Sertraline Citalopram	1.25 (0.98 – 1.60) 1.44 (1.12 – 1.86) 0.93 (0.70 – 1.24) 1.03 (0.80 – 1.32)	33% (0.19) 0% (0.82) 63% (0.03) 0% (0.58)	Individual antidepressants investigated Population heterogeneity explored 5 databases investigated Includes data outside of live births	Limited to SSRIs only
Grigoriadis, et al. 2013 ¹³	Embase, CINAHL, PsycINFO and Medline (inception to June 2010)	13 studies, cohort and case-control	Systematic Assessment of Quality in Observational Research	1,547,012	Any antidepressant	1.36 (1.08 – 1.71)	31.1% (0.134)	Live births, fetal deaths and terminations of pregnancy included	Considers multiple antidepressants Four of 13 studies had comparison groups which had used antidepressants
Bar-Oz, et al. 2007 ⁹	Medline, Embase, Reprotox, Scopus and Biological Abstracts (1985 to 2006)	6 studies: 1 nested case control, 2 prospective controlled, 1 population-based cohort, 1 retrospective cohort, 1 prospective recording registry	Downs and Black	16,789	Paroxetine	1.72 (1.22 – 2.42)	n.d.	5 data sources investigated	Small number of pregnant women Includes abstracts and a letter 3 control groups used other SSRIs Heterogeneity not investigated Live births only

OR, odds ratio; RR, relative risk; CI, confidence interval; T1, First trimester of pregnancy; SSRI, selective serotonin reuptake inhibitor; n.d., no data

Meanings Of Study

This meta-analysis has demonstrated that using antidepressants during the first trimester of pregnancy increases the overall risk for congenital heart defects. TCAs were the only group of antidepressants investigated in this study which did not show an increased odds ratio between maternal use and congenital heart defects. In comparison, SNRIs and SSRIs demonstrated an approximate increased likelihood for congenital heart defects of 1.5 and 1.2 times that of the unmedicated comparison group, respectively.

Analyses of individual antidepressants revealed that the SSRIs paroxetine, fluoxetine and sertraline increased the likelihood of congenital heart defects by 1.5, 1.3 and 1.3 times that of the comparison group respectively. Analyses of individual antidepressants revealed that the SNRI bupropion increased the likelihood of congenital heart defects by 1.2 times that of the comparison group.

Less information is available for some antidepressants such as desvenlafaxine or fluvoxamine, despite desvenlafaxine being the most dispensed psycho-analeptic medication in women of child-bearing age in Australia in 2013.³⁶ It is also necessary to investigate risks associated for fluvoxamine because even though it is not as commonly used, medications may become more popular over time or be repurposed.

This meta-analysis has investigated the likelihood of antidepressants causing congenital heart defects however these medications may have other adverse effects which should also be investigated. Therefore, care should be taken when prescribing antidepressant medications to women who are likely to become pregnant, as switching or withdrawing antidepressant therapy is a slow process. Antidepressant therapy can also be ceased prior to conception for women who are well and perhaps more of an emphasis should be placed upon withdrawing medications if they are not needed.

Future Directions

More pharmacoepidemiological data is needed to build a case for the risk of individual antidepressants causing congenital heart defects, especially those which have not been well studied such as desvenlafaxine and fluvoxamine. Ideally, analyses of all individual antidepressant medications should be completed in the context of other harmful pregnancy outcomes to identify which antidepressants present less risks during pregnancy than others.

If biological targets which play a key role in cardiac formation could be identified, this information could be used to detect medications which may cause congenital heart defects. Firstly, genes involved in cardiac defects can be identified from online sources, such as the Comparative Toxicogenomics Database (<http://ctdbase.org/>). The most promising genes can be investigated to determine if medications can directly interact with them and molecular modelling may be undertaken, particularly if X-ray crystal structures exist. Medications of interest can be computationally docked into the appropriate binding site to enable potential identification of antidepressants or other medications which may cause congenital heart defects. Laboratory luciferase assays may provide additional evidence for any suspected harmful medications which are identified.

The aim of future work is therefore to identify which medicines may cause congenital heart defects by investigating the mechanisms behind medication-related cardiac malformations.

Conclusions

Maternal usage of antidepressants during the first trimester of pregnancy increases the risk for congenital heart defects by approximately 1.2 times that of the group not using antidepressants during

pregnancy. SNRI and SSRI antidepressants showed an increased risk of 1.5 and 1.2 times respectively, while TCAs were not found to have an increased risk. Individual SSRIs paroxetine, fluoxetine and sertraline have demonstrated an approximate increased likelihood of congenital heart defects by 1.5, 1.3 and 1.3 times respectively. The SNRI bupropion also demonstrated an approximate 1.2 times increased likelihood of congenital heart defects.

More information is needed about the risks of individual antidepressants, especially for desvenlafaxine, the most dispensed psycho-analeptic in Australia during 2013. The mechanism of antidepressant-related heart defects is currently unknown and future computational and laboratory work could be undertaken to understand these mechanisms and to potentially identify other medications which increase the risk of congenital heart defects.

Footnotes

Contributors: ER and CDV designed the study. CDV did the literature search. CDV and SG extracted data from the identified articles. CDV did the meta-analyses and drafted the manuscript. All authors reviewed the manuscript, contributed to its revision and approved the final version submitted.

Funding: This work was supported by an Australian Government Research Training Program scholarship and NHMRC APP 1110139.

Competing interests: All authors have completed the ICMJE uniform disclosure form at and declare: no support from any organisation for the submitted work; the University of South Australia received payments from the Australian Government Research Training Program, which is a PhD student scholarship, with no financial relationships with any other organisations that might have an interest in the submitted work in the previous three years, excepting no other relationships or activities that could appear to have influenced the submitted work.

License statement: CDV has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution and convert or allow conversion into any format including without limitation audio, iii) create any other derivative work(s) based in whole or part on the on the Contribution, iv) to exploit all subsidiary rights to exploit all subsidiary rights that currently exist or as may exist in the future in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above. All research articles will be made available on an open access basis (with authors being asked to pay an open access fee). The terms of such open access shall be governed by a Creative Commons licence—details as to which Creative Commons licence will apply to the research article are set out in our worldwide licence referred to above.

Ethical approval: Not needed.

Data sharing: Additional data is provided in the supplementary files.

Transparency: The corresponding author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

Patient and Public Involvement Statement: Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Dissemination Declaration: Dissemination to study participants or patient organisations is not possible/applicable.

References

1. Jimenez-Solem E, Andersen JT, Petersen M, et al. Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort study. *PLoS ONE* 2013;8:e63034. doi:10.1371/journal.pone.0063034
2. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernandez-Diaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. *AJOG* 2011;205:e1-e8.
3. Hanley GE, Mintzes B. Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. *BMC Pregnancy Childbirth* 2014;14:242. doi:10.1186/1471-2393-14-242
4. Williams M, Wooltorton E. Paroxetine (Paxil) and congenital malformations. *Cmaj* 2005;173:1320-1. doi:10.1503/cmaj.051421
5. Berard A, Iessa N, Chaabane S, Muanda FT, Boukhris T, Zhao JP. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis. *Br J Clin Pharmacol* 2016;81:589-604. doi:10.1111/bcp.12849
6. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. *J Psychiatry Neurosci* 2001;26:44-8.
7. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. *Jama* 2006;295:499-507. doi:10.1001/jama.295.5.499
8. Myles N, Newall H, Ward H, Large M. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. *Aust N Z J Psychiatry* 2013;47:1002-12. doi:10.1177/0004867413492219
9. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. *Clin Ther* 2007;29:918-26. doi:10.1016/j.clinthera.2007.05.003
10. Gao SY, Wu QJ, Zhang TN, et al. Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies. *Br J Clin Pharmacol* 2017;83:2134-47. doi:10.1111/bcp.13321
11. Riggan L, Frankel Z, Moretti M, Pupco A, Koren G. The fetal safety of fluoxetine: a systematic review and meta-analysis. *JOGC* 2013;35:362-9. doi:10.1016/s1701-2163(15)30965-8
12. Shen ZQ, Gao SY, Li SX, et al. Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies. *Br J Clin Pharmacol* 2017;83:909-22. doi:10.1111/bcp.13161
13. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. *J Clin Psychiatry* 2013;74:e293-308. doi:10.4088/JCP.12r07966
14. Ban L, Gibson JE, West J, et al. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study. *Bjog* 2014;121:1471-81. doi:10.1111/1471-0528.12682
15. Berard A, Zhao JP, Sheehy O. Sertraline use during pregnancy and the risk of major malformations. *Am J Obstet Gynecol* 2015;212:795.e1-.e12. doi:10.1016/j.ajog.2015.01.034
16. Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. *Bmj* 2015;350:h1798. doi:10.1136/bmj.h1798
17. Knudsen TM, Hansen AV, Garne E, Andersen AMN. Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy - an epidemiological study using validated EUROCAT data. *BMC Pregnancy Childbirth* 2014;14:
18. Louik C, Kerr S, Mitchell AA. First-trimester exposure to bupropion and risk of cardiac malformations. *Pharmacoepidemiol Drug Saf* 2014;23:1066-75. doi:10.1002/pds.3661
19. Hartling L, Milne A, Hamm M, et al. Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers. *J Clin Epidemiol* 2013;66:982-3. doi:10.1016/j.jclinepi.2013.03.003

20. Lo C, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. *BMC Med Res Methodol* 2014;14:45. doi:10.1186/1471-2288-14-45.
21. Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. *Pharmacoepidemiol Drug Saf* 2007;16:1086-94. doi:10.1002/pds.1462
22. Review Manager (RevMan) [program]. 5.4 version. Copenhagen: The Cochrane Collaboration, 2014.
23. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. *N Engl J Med* 2014;370:2397-407. doi:10.1056/NEJMoa1312828
24. Jordan S, Morris JK, Davies GI, et al. Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in Pregnancy and Congenital Anomalies: Analysis of Linked Databases in Wales, Norway and Funen, Denmark. *PloS One* 2016;11:e0165122. doi:10.1371/journal.pone.0165122
25. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. *Jama* 1998;279:609-10. doi:10.1001/jama.279.8.609
26. Margulis AV, Abou-Ali A, Strazzeri MM, et al. Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD. *Pharmacoepidemiol Drug Saf* 2013;22:942-51. doi:10.1002/pds.3462
27. Nordeng H, Van Gelder MMHJ, Spigset O, Koren G, Einarson A, Eberhard-Gran M. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: Results from the Norwegian mother and child cohort study. *J Clin Psychopharmacol* 2012;32:186-94.
28. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. *Birth Defects Res B Dev Reprod Toxicol* 2008;83:68-76. doi:10.1002/bdrb.20144
29. Vasilakis-Scaramozza C, Aschengrau A, Cabral H, Jick SS. Antidepressant use during early pregnancy and the risk of congenital anomalies. *Pharmacotherapy* 2013;33:693-700. doi:10.1002/phar.1211
30. Alwan S, Reefhuis J, Botto LD, Rasmussen SA, Correa A, Friedman JM. Maternal use of bupropion and risk for congenital heart defects. *AJOG* 2010;203:52.e1-6. doi:10.1016/j.ajog.2010.02.015
31. De Jonge L, Zetstra-Van Der Woude PA, Bos HJ, De Jong-Van Den Berg LTW, Bakker MK. Identifying associations between maternal medication use and birth defects using a case-population approach: An exploratory study on signal detection. *Drug Saf* 2013;36:1069-78. doi:10.1007/s40264-013-0082-2.
32. Polen KND, Rasmussen SA, Riehle-Colarusso T, Reefhuis J. Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007. *Birth Defects Res A Clin Mol Teratol* 2013;97:28-35.
33. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. *Br J Clin Pharmacol* 2008;66:695-705. doi:10.1111/j.1365-2125.2008.03261.x
34. Lambert O, Bourin M. SNRIs: mechanism of action and clinical features. *Expert Review of Neurotherapeutics* 2002;2:849-58. doi:10.1586/14737175.2.6.849
35. Sangkuhl K, Klein TE, Altman RB. Selective serotonin reuptake inhibitors pathway. *Pharmacogenetics and genomics* 2009;19:907-9. doi:10.1097/FPC.0b013e32833132cb
36. Gadzhanova S, Roughead E. Use of prescription medicines in Australian women of child-bearing age. *BMC Pharmacology and Toxicology* 2015;16:doi:10.1186/s40360-015-0033-x
37. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. *Birth Defects Research Part A - Clinical and Molecular Teratology* 2011;91:142-52. doi:10.1002/bdra.20773
38. Merlob P, Birk E, Sirota L, et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. *Birth Defects Res A Clin Mol Teratol* 2009;85:837-41. doi:10.1002/bdra.20615

39. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Norgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: Updated analysis. *Clinical Epidemiology* 2010;2:29-36.
40. Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. *Birth Defects Res A Clin Mol Teratol* 2007;79:301-8. doi:10.1002/bdra.20327
41. Jimenez-Solem E, Andersen JT, Petersen M, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: A nationwide cohort study. *BMJ Open* 2012;2:
42. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. *Obstet Gynecol* 2011;118:111-20. doi:10.1097/AOG.0b013e318220edcc
43. Mann CJ. Observational research methods. research design II: cohort, cross sectional, and case-control studies. *EMJ* 2003;20:54. doi:10.1136/emj.20.1.54
44. Norvell DC. Study types and bias - don't judge a study by the abstract's conclusion alone. *Evid Based Spine Care J* 2010;1:7-10. doi:10.1055/s-0028-1100908
45. Zhang Y-F, Zeng X-L, Zhao E-F, Lu H-W. Diagnostic value of fetal echocardiography for congenital heart disease: a systematic review and meta-analysis. *Medicine* 2015;94:e1759. doi:10.1097/MD.0000000000001759

Electronic databases (n=2973):
PubMed (n=809) Embase (n=2164)

Duplicates removed (n=287)

Title or abstract reviews (n=2686)

Failed title or abstract reviews (n=2601)

Full-text review (n=85)

Excluded (n=69):

Not a cohort or case-control study (n=25)

Overlapping study (n=12)

No cardiac defect outcomes measured (n=12)

No antidepressant usage (n=7)

Comparison group is unsuitable (n=7)

Failed study inclusion criteria (n=4)

Not first trimester antidepressant use (n=2)

Included in meta-analysis (n=16):

Cohort studies (n=12)

Case-control studies (n=4)

Study or Subgroup	Cohort / Case		Comparison		Weight	Odds Ratio (95% CI)	Mantel-Haenszel, Random, 95% CI	Odds Ratio
	Events	Total	Events	Total				
Paroxetine								
Jordan 2016	17	1069	4047	449643	2.2%	1.78 [1.10, 2.88]		
Furu 2015	53	2879	26745	2266875	5.0%	1.57 [1.20, 2.06]		
Ban 2014	17	1200	2556	338726	2.2%	1.89 [1.17, 3.06]		
Huybrechts 2014	93	11126	6403	885115	6.7%	1.16 [0.94, 1.42]		
De Jonge 2013	3	873	65	29223	0.4%	1.55 [0.49, 4.93]		
Nordeng 2012	1	76	541	61648	0.2%	2.26 [0.31, 16.38]		
Oberlander 2008	7	993	512	107320	1.0%	1.48 [0.70, 3.13]		
Diav-Citrin 2008	7	348	8	1359	0.6%	3.47 [1.25, 9.63]		
Davis 2007	4	182	1184	49654	0.6%	0.92 [0.34, 2.48]		
Subtotal (95% CI)	210	18746	42177	4189563	19.8%	1.53 [1.25, 1.88]		
Heterogeneity: Tau ² = 0.03; Chi ² = 11.70, df = 8 (P = 0.17); I ² = 32%								
Test for overall effect: Z = 4.17 (P < 0.0001)								
Fluoxetine								
Jordan 2016	21	2601	4047	449643	2.6%	0.90 [0.58, 1.38]		
Furu 2015	106	6250	26745	2266875	7.2%	1.45 [1.19, 1.75]		
Ban 2014	21	3189	2556	338726	2.6%	0.87 [0.57, 1.34]		
Huybrechts 2014	99	11048	6403	885115	6.9%	1.24 [1.02, 1.51]		
De Jonge 2013	3	873	65	29223	0.4%	1.55 [0.49, 4.93]		
Nordeng 2012	1	51	541	61648	0.2%	2.26 [0.31, 16.38]		
Oberlander 2008	5	638	512	107320	0.7%	1.65 [0.68, 3.99]		
Diav-Citrin 2008	7	253	8	1359	0.6%	4.81 [1.73, 13.37]		
Subtotal (95% CI)	263	24903	40877	4139909	21.2%	1.28 [1.01, 1.62]		
Heterogeneity: Tau ² = 0.04; Chi ² = 14.53, df = 7 (P = 0.04); I ² = 52%								
Test for overall effect: Z = 2.04 (P = 0.04)								
Sertraline								
Jordan 2016	17	1374	4047	449643	2.2%	1.38 [0.85, 2.23]		
Berard 2015	10	366	344	14868	1.3%	1.19 [0.63, 2.24]		
Furu 2015	109	7245	26745	2266875	7.2%	1.28 [1.06, 1.55]		
Ban 2014	9	757	2556	338726	1.3%	1.58 [0.82, 3.06]		
Huybrechts 2014	129	14040	6403	885115	7.7%	1.27 [1.07, 1.52]		
Nordeng 2012	1	99	541	61648	0.2%	1.15 [0.16, 8.28]		
Oberlander 2008	3	608	512	107320	0.5%	1.03 [0.33, 3.23]		
Subtotal (95% CI)	278	24489	41148	4124195	20.4%	1.28 [1.14, 1.45]		
Heterogeneity: Tau ² = 0.00; Chi ² = 0.69, df = 6 (P = 0.99); I ² = 0%								
Test for overall effect: Z = 4.12 (P < 0.0001)								
Citalopram								
Jordan 2016	40	4028	4047	449643	4.2%	1.10 [0.81, 1.51]		
Furu 2015	176	11193	26745	2266875	8.6%	1.34 [1.15, 1.55]		
Ban 2014	17	1946	2556	338726	2.2%	1.16 [0.72, 1.87]		
De Jonge 2013	0	873	35	29223	0.1%	0.47 [0.03, 7.68]		
Oberlander 2008	3	101	512	107320	0.4%	6.39 [2.02, 20.21]		
Subtotal (95% CI)	236	18141	33895	3191787	15.5%	1.33 [0.98, 1.81]		
Heterogeneity: Tau ² = 0.06; Chi ² = 9.29, df = 4 (P = 0.05); I ² = 57%								
Test for overall effect: Z = 1.82 (P = 0.07)								
Escitalopram								
Jordan 2016	21	3236	4047	449643	2.6%	0.72 [0.47, 1.11]		
Furu 2015	46	3950	26745	2266875	4.6%	0.99 [0.74, 1.32]		
Ban 2014	3	333	2556	338726	0.5%	1.20 [0.38, 3.73]		
Subtotal (95% CI)	70	7519	33348	3055244	7.7%	0.90 [0.71, 1.15]		
Heterogeneity: Tau ² = 0.00; Chi ² = 1.68, df = 2 (P = 0.43); I ² = 0%								
Test for overall effect: Z = 0.83 (P = 0.41)								
Fluvoxamine								
Jordan 2016	0	28	4047	449643	0.1%	1.93 [0.12, 31.64]		
Furu 2015	0	255	26745	2266875	0.1%	0.16 [0.01, 2.63]		
Oberlander 2008	0	119	512	107320	0.1%	0.87 [0.05, 14.04]		
Subtotal (95% CI)	0	402	31304	2823838	0.2%	0.65 [0.13, 3.23]		
Heterogeneity: Tau ² = 0.00; Chi ² = 1.97, df = 2 (P = 0.37); I ² = 0%								
Test for overall effect: Z = 0.53 (P = 0.60)								
Venlafaxine								
Furu 2015	40	2763	26745	2266875	4.2%	1.23 [0.90, 1.68]		
Oberlander 2008	1	250	512	107320	0.2%	0.84 [0.12, 5.98]		
Polen 2013	74	15758	12	4038	1.4%	1.58 [0.86, 2.92]		
Subtotal (95% CI)	115	18771	27269	2378233	5.8%	1.29 [0.98, 1.69]		
Heterogeneity: Tau ² = 0.00; Chi ² = 0.71, df = 2 (P = 0.70); I ² = 0%								
Test for overall effect: Z = 1.79 (P = 0.07)								
Bupropion								
Louik 2014	19	4676	19	8611	1.3%	1.84 [0.98, 3.49]		
Huybrechts 2014	76	8856	6403	885115	6.1%	1.19 [0.95, 1.49]		
Alwan 2010	34	6853	26	5869	2.0%	1.12 [0.67, 1.87]		
Subtotal (95% CI)	129	20385	6448	899595	9.4%	1.23 [1.01, 1.50]		
Heterogeneity: Tau ² = 0.00; Chi ² = 1.77, df = 2 (P = 0.41); I ² = 0%								
Test for overall effect: Z = 2.04 (P = 0.04)								
Total (95% CI)	1310	133356	256466	24802364	100.0%	1.28 [1.19, 1.39]		
Heterogeneity: Tau ² = 0.01; Chi ² = 53.68, df = 40 (P = 0.07); I ² = 25%								
Test for overall effect: Z = 6.26 (P < 0.00001)								
Test for subgroup differences: Chi ² = 12.23, df = 7 (P = 0.09), I ² = 42.8%								

medRxiv preprint doi: <https://doi.org/10.1101/2020.02.24.20027532>; this version posted February 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.